Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00088478
Status:
COMPLETED
Last Update Posted:
2007-06-12
First Post:
2004-07-26
Brief Title:
Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Double-Blind Randomized Study Comparing Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia
Status:
COMPLETED
Status Verified Date:
2007-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Key objectives of this clinical study are to
Determine how well intramuscular IM olanzapine depot works compared to placebo
Evaluate the safety and tolerability of IM olanzapine depot compared to placebo
Evaluate different doses of IM olanzapine depot compared to placebo to identify the best doses
Determine how well intramuscular IM olanzapine depot works compared to placebo
Evaluate the safety and tolerability of IM olanzapine depot compared to placebo
Evaluate different doses of IM olanzapine depot compared to placebo to identify the best doses
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| F1D-MC-HGJZ | None | None | None |